Minaris Regenerative Medicine Streamlining Contract Manufacturing with Veeva Vault Quality Suite Applications

Global CDMO unifies quality content and training for greater visibility and agility

PLEASANTON, Calif., May 24, 2023 /PRNewswire/ -- Veeva Systems (NYSE: VEEV) today announced that Minaris Regenerative Medicine, a leading contract development and manufacturing organization (CDMO) focused on cell and gene therapies, selected Veeva Vault QualityDocs and Veeva Vault Training to advance its global quality operations. Minaris Regenerative Medicine will use Veeva's unified quality applications to better collaborate with customers and partners, improve transparency across functions, and ensure compliance. 

"As a pioneer in cell and gene therapy, we needed a scalable quality management foundation to drive efficiency and compliance," said Prakash Manwani, chief digital officer, Minaris Regenerative Medicine. "With Veeva Vault Quality Suite applications, we are well-positioned for GxP document control and continuous quality improvement. Veeva as a platform is a critical piece of our global IT roadmap and vision to create a digitally connected ecosystem for our operations, customers, and patients alike."

Minaris Regenerative Medicine's vision is "creating future cell therapy miracles together," and the Veeva platform will advance its ability to do so, to the benefit of both its clients and those patients suffering from a wide range of diseases for which cell and gene therapy holds promise. The CDMO will use Veeva Vault Quality Suite applications to modernize its operations globally, including Vault QualityDocs to control access and distribution of content and Vault Training to create and manage role-based learning programs. By adopting connected applications on a single platform, Minaris Regenerative Medicine will streamline its global quality processes.

"Veeva gives us easy access to documentation and training for more agility on site," said Adela Balducci, executive director, head of quality, North America, Minaris Regenerative Medicine. "Being on the same platform as many of our customers will deliver efficiencies in information sharing and reporting, improving how we work with clients for a competitive edge."    

"Minaris Regenerative Medicine is developing and manufacturing potentially life-changing cell therapies to treat cancers and genetic disorders that do not have any known cures," said Ashley McMillan, senior director, Veeva Vault Quality strategy. "Veeva Vault Quality applications will be key in supporting quality for these important therapies. We're excited to be a strategic partner helping them transform content and employee qualification management."

Additional Information
For more on Veeva Vault Quality Suite, visit: veeva.com/Quality Manufacturing Connect with Veeva on LinkedIn: linkedin.com/company/veeva-systems

About Minaris Regenerative Medicine 
Minaris Regenerative Medicine is a global contract development and manufacturing organization (CDMO) for cell and gene therapies. We offer our clients high-value clinical and commercial manufacturing services, development solutions, and technologies. We are pioneers in the field with more than 20 years of experience providing outstanding quality and reliability. Our facilities in North America, Europe, and Asia allow us to supply life-changing therapies to patients globally. Minaris Regenerative Medicine is part of the Resonac Group.

For more information, please visit www.rm.minaris.com.

About Veeva Systems
Veeva is the global leader in cloud software for the life sciences industry. Committed to innovation, product excellence, and customer success, Veeva serves more than 1,000 customers, ranging from the world's largest biopharmaceutical companies to emerging biotechs. As a Public Benefit Corporation, Veeva is committed to balancing the interests of all stakeholders, including customers, employees, shareholders, and the industries it serves. For more information, visit veeva.com.

Veeva Forward-looking Statements
This release contains forward-looking statements regarding Veeva's products and services and the expected results or benefits from use of our products and services. These statements are based on our current expectations. Actual results could differ materially from those provided in this release and we have no obligation to update such statements. There are numerous risks that have the potential to negatively impact our results, including the risks and uncertainties disclosed in our filing on Form 10-K for the fiscal year ended January 31, 2023, which you can find here (a summary of risks which may impact our business can be found on pages 9 and 10), and in our subsequent SEC filings, which you can access at sec.gov.

Contact:

Deivis Mercado
Veeva Systems
925-226-8821
[email protected]

SOURCE Veeva Systems